Locally Advanced or Metastatic (Merck 7339-007) Temp Enrollment Hold

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Location: CPMC (San Francisco)

Please contact: Clinicalresearch@sutterhealth.org for information about Merck 7339-007

Principal Investigator

Wei Wang, MD

Co-Investigator(s)

Lejla Delic, MD, Kevin Kim, MD 

Recruitment Status

Active, Not Recruiting

Start Date

December 20, 2019